ArticleClinical lymphoma, myeloma & leukemia2015
Characteristics of Sweet Syndrome in patients with acute myeloid leukemia.
Article in Clinical lymphoma, myeloma & leukemia, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 67 citations in OpenAlex.
- Article
- When the Skin Speaks for the Bone Marrow: Sweet Syndrome and Pancytopenia as the Initial Manifestation of Occult AML.International journal of hematology-oncology and stem cell research · 2026Article
- Sweet Syndrome-like Dermatosis as a Precursor to Overlapping Hematologic Malignancies: A Case Report and Review.Journal of clinical medicine · 2025Review
- Complex Interplay Between Sweet Syndrome and Therapy-Related Myelodysplastic Syndrome After B-Cell Lymphoma Treatment: A Case Report.The American journal of case reports · 2025Article
- Article
- Sweet's Syndrome as a Prodromal Manifestation of Acute Myeloid Leukemia.International journal of hematology-oncology and stem cell research · 2025Article
- Acute myeloid leukemia withThe Journal of international medical research · 2025Review
- Upper Respiratory Tract Infection Leading to a New Diagnosis of Sweet Syndrome and Monoclonal Gammopathy of Unknown Significance.HCA healthcare journal of medicine · 2025Article
- Expanding subcutaneous mass on the scalp of an immunocompromised woman.Skin health and disease · 2024Article
- Article
- Infiltrative and sclerotic right chest wall plaque.JAAD case reports · 2024Article
- Acute Febrile Neutrophilic Dermatosis (Sweet Syndrome) in Acute Myeloid Leukemia Patients: A 28-Year Institutional Experience.Acta haematologica · 2024Article
- Sweet Syndrome: Clinical Presentation, Malignancy Association, Autoinflammatory Disorders and Treatment Response in a Cohort of 93 Patients with Long-term Follow-up.Acta dermato-venereologica · 2023Article
- Article
- Sweet Syndrome Associated with Myelodysplastic Syndrome-A Review of a Multidisciplinary Approach.Life (Basel, Switzerland) · 2023Review
- An uncommon culprit of neutropenic fever: a case of Sweet syndrome following induction therapy for acute myeloid leukemia.Archive of clinical cases · 2023Article
- Unique challenges to diagnosing sweet syndrome following induction chemotherapy for relapsed Acute Myeloid Leukemia (AML): A case and brief-review.Respiratory medicine case reports · 2023Article
- Azacytidine-induced Sweet's syndrome.BMJ case reports · 2022Article
- Bullous Sweet Syndrome.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2022Article
- New Practical Aspects of Sweet Syndrome.American journal of clinical dermatology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
Abstract
introductionSweet syndrome (SS) is associated with hematologic malignancies including acute myeloid leukemia (AML). PATIENTS AND
methodsRecords of patients with AML treated at our institution were reviewed to identify those with SS. Patient characteristics, laboratory values, and cytogenetic and molecular abnormalities were retrospectively reviewed.
resultsWe identified 21 of 2178 (1%) AML patients who demonstrated clinical signs and symptoms, and histological features consistent with SS. Eleven patients (52%) were classified as AML with myelodysplasia-related features and 3 patients had therapy-related AML. Three patients had received treatment with granulocyte colony stimulation factor, 1 patient liposomal all-trans-retinoic acid, and 2 patients received hypomethylating agents before development of SS. Cytogenetic analysis revealed diploid karyotype in 7 patients (33%); -5/del(5q) in 8 patients (38%): 3 patients had -5/del(5q) as the sole abnormality and 5 patients had -5/del(5q) as part of complex cytogenetics; and complex cytogenetics in 5 patients (24%). Gene mutations in FMS-related tyrosine kinase-3 (FLT3) gene were identified in 7 of 18 evaluable patients (39%), including FLT3-internal tandem duplication in 4 patients and FLT3-D835 tyrosine kinase domain mutation in 3 patients.
conclusionSS occurs in 1% of AML patients; -5/del(5q) karyotype, FLT3 mutations, and AML with myelodysplasia-related features were more frequent among patients with SS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.